Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs

• Váldodahkkit: Lukas von Bredow (Dahkki), Thomas Martin Schäfer (Dahkki), Julian Hogenkamp (Dahkki), Maik Tretbar (Dahkki), Daniel Stopper (Dahkki), Fabian B. Kraft (Dahkki), Julian Schliehe-Diecks (Dahkki), Andrea Schöler (Dahkki), Arndt Borkhardt (Dahkki), Sanil Bhatia (Dahkki), Jana Held (Dahkki), Finn K. Hansen (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2022-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Artemisinin-based combination therapies (ACTs) are the gold standard for the treatment of malaria, but the efficacy is threatened by the development of parasite resistance. Histone deacetylase inhibitors (HDACis) are an emerging new class of potential antiplasmodial drugs. In this work, we present t...